SGLT2 inhibitors – why a synthesis of empagliflozin is a significant progression in diabetes pharmacotherapy? Review article
Article Sidebar
Published:
Jun 30, 2020
Keywords:
type 2 diabetes, empagliflozin, flosin, heart failure, SGLT2
Main Article Content
Abstract
Empagliflozin is the first hypoglycaemic drug with proven cardiovascular safety and reduces the risk of death from any cause. Empagliflozin reduce glucose reabsorption, inhibiting SGLT2 in the kidneys. This induces glucosuria, which causes loss of energy and glucose in the urine and resulting in improved glycemic control, diabetes control and weight loss. In the EMPA-REG OUTCOME study empagliflozine in combination with standard diabetes therapy reduced the risk of cardiovascular death, stroke or non-fatal stroke by 14% and reduced overall mortality by 32%.
Article Details
How to Cite
Woroń , J. (2020). SGLT2 inhibitors – why a synthesis of empagliflozin is a significant progression in diabetes pharmacotherapy?. Medycyna Faktow (J EBM), 13(2(47), 147-150. https://doi.org/10.24292/01.MF.0220.2
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Lanas A. NSAID and Aspirin, Recent Advances and Implications for Clinical Management. Springer International Publishing, Switzerland 2016.
2. Chisholm-Burns MA, Schwinghammer TL, Malone PM et al. Pharmacotherapy Principles & Practice. McGraw-Hill Education, New York 2019.
3. Rosenthal LD, Burchum JR. Pharmacotherapeutics for Advances Practice Providers. Elsevier, St Louis 2018.
4. DiPiro JT, Talbert LR, Yee GC et al. Pharmacotherapy, a Pathophysiologic Approach. McGraw-Hill Education, New York 2017.
5. Wirfs MJ. Prescribing Drug Therapy. Springer Publishing Company, New York 2019.
6. Czupryniak L, Strojek K. Diabetologia 2019. Via Medica, Gdańsk 2019.
2. Chisholm-Burns MA, Schwinghammer TL, Malone PM et al. Pharmacotherapy Principles & Practice. McGraw-Hill Education, New York 2019.
3. Rosenthal LD, Burchum JR. Pharmacotherapeutics for Advances Practice Providers. Elsevier, St Louis 2018.
4. DiPiro JT, Talbert LR, Yee GC et al. Pharmacotherapy, a Pathophysiologic Approach. McGraw-Hill Education, New York 2017.
5. Wirfs MJ. Prescribing Drug Therapy. Springer Publishing Company, New York 2019.
6. Czupryniak L, Strojek K. Diabetologia 2019. Via Medica, Gdańsk 2019.